TRAF3IP2抗体

The TRAF3IP2 (TRAF3 Interacting Protein 2) antibody is a tool used to study the TRAF3IP2 protein, a key adaptor molecule involved in inflammatory and immune signaling pathways. TRAF3IP2. also known as ACT1 or CIKS, interacts with TRAF proteins (TNF receptor-associated factors) to mediate signals from cytokine receptors, such as IL-17 receptors, and regulates activation of NF-κB and JNK pathways. Its role in modulating immune responses links it to autoimmune diseases like psoriasis, rheumatoid arthritis, and lupus, as well as cancer progression. Antibodies targeting TRAF3IP2 enable researchers to detect its expression, localization, and interactions in cells or tissues. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate TRAF3IP2’s involvement in disease mechanisms or therapeutic targeting. Studies using TRAF3IP2 antibodies have revealed its overexpression in certain cancers and its regulatory effects on pro-inflammatory cytokines, making it a potential biomarker or drug target. Validation of these antibodies often includes knockout controls to ensure specificity, as TRAF3IP2 shares functional domains with other signaling proteins. Overall, TRAF3IP2 antibodies are vital for dissecting its contributions to immune dysregulation and developing precision therapies.